An application has been submitted to Japan's Ministry of Health, Labor and Welfare for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Original Article: Japanese Approval Sought for Darolutamide in Nonmetastatic CRPC